Patents Represented by Attorney Amylin Pharmaceuticals, Inc.

Find this attorney in the Justia Lawyer Directory

  • Exendin agonist compounds
    Patent number: 8263550
    Abstract: Novel exendin agonist compounds are provided. These compounds are useful in treating Type I and II diabetes and conditions which would benefit by lower plasma glucose and delaying and/or slowing gastric emptying.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: September 11, 2012
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett
  • Methods for regulating postprandial blood glucose
    Patent number: 7407934
    Abstract: Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are also described.
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: August 5, 2008
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Orville G. Kolterman, Andrew A. Young, Timothy J. Rink, Kathleen Ann Keating Brown
  • Methods for affecting body composition
    Patent number: 7399744
    Abstract: Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: July 15, 2008
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Christine Marie Mack, Jonathan David Roth
  • Methods of increasing lean tissue mass using OB protein compositions
    Patent number: 7208577
    Abstract: The present invention provides methods of creating and using OB protein compositions with an antibody constant region or portion thereof fused to an OB protein. The fusion protein is created by attaching the polyamino acids to the OB protein moiety. The fusion proteins can then be used for various therapeutic uses.
    Type: Grant
    Filed: January 11, 2005
    Date of Patent: April 24, 2007
    Assignee: Amgen, Inc.
    Inventors: Mary Ann Pelleymounter, Christopher Francis Toombs, Michael Benjamin Mann
  • Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
    Patent number: 7183254
    Abstract: Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: February 27, 2007
    Assignee: Amgen, Inc.
    Inventors: Alexander M. DePaoli, Simeon I. Taylor, Elif A. Oral, Abhimanyu Garg